Effect of fibrynolytic therapy on CTEPH

effect of fibrynolytic therapy on incidence of chronic thromboembolic pulmonary hypertention(CTEPH) in patient with high risk Submassive Pulmonary thromboembolism

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190301042873N1

Enrollment

Registered

2022-03-07

Start date

2020-07-08

Completion date

Unknown

Last updated

2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Pulmonary Embolism. Condition 2: Chronic Thromboembolic Pulmonary Hypertension. Pulmonary embolism Chronic pulmonary embolism

Interventions

Intervention 1: Intervention group: fibrinilytic therapy with streptokinase 2500000 IU IV bolus then 10000 IU/hour IV infusion 12-24 hour. Then bridging therapy will initiate within two days after PT

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with high-risk Submassive pulmonary emboli;those patients with acute PE without systemic hypotension but with evidence of either right ventricle (RV) dysfunction or myocardial necrosis

Exclusion criteria

Exclusion criteria: Patients with history of chronic thromboembolic pulmonary hypertension (CTEPH)

Design outcomes

Primary

Measure	Time frame
Prevalence of chronic thromboembolic PH(CTEPH) after 3 month therapy (anticoagulant or fibrinolytic) in two groups. Timepoint: comparision of mean LVEF after 3 month standard anticoagulant therapy. Method of measurement: comparision of mean RV function with TAPSE after 3 month standard anticoagulant therapy.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Hadi Mansouri

Esfahan University of Medical Sciences

Drhadimansouri@gmail.com+98 31 3611 5310

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026